A variety of antiestrogens can be shown to antagonize estrogen action in animal model systems. Several of these compounds are useful in the management of metastatic human breast cancer. To further elucidate their mechanism of action, we studied several of these compounds using human breast cancer cell lines maintained in long term tissue culture as a model system. Antiestrogens including tamoxifen (NSC 180973; ICI 46474), nafoxidine, CI 628, and clomiphene citrate inhibit macromolecular synthesis below control levels in two human breast cell lines. This effect is limited to cell lines which contain estrogen receptors. Simultaneous addition of as little as 1000 fold less estradiol prevents antiestrogen effects. Sequential addition of estrogen for up to 48 hours to cells incubated in antiestrogen reverses inhibition. If cells are continued in antiestrogen alone for more than about 3 days, inhibitory effects become irreversible. The cells detach from the surface of the culture vessel and are no longer viable. Tamoxifen competes with 3H estradiol for specific receptor sites but with about a 100 fold lower apparent affinity. Direct binding of 3H tamoxifen and 3H estradiol to duplicate cytoplasmic extracts reveals equivalent numbers of binding sites but a 20 fold lower affinity for the antiestrogen. There is reasonable agreement between concentrations of tamoxifen which bind to receptor and concentrations which inhibit cells.
|Original language||English (US)|
|Number of pages||9|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1976|
ASJC Scopus subject areas
- Cancer Research